Artificial intelligence and science of patient input: a perspective from people with multiple sclerosis.

Journal: Frontiers in immunology
PMID:

Abstract

Artificial intelligence (AI) can play a vital role in achieving a shift towards predictive, preventive, and personalized medicine, provided we are guided by the science with and of patient input. Patient-reported outcome measures (PROMs) represent a unique opportunity to capture experiential knowledge from people living with health conditions and make it scientifically relevant for all other stakeholders. Despite this, there is limited uptake of the use of standardized outcomes including PROMs within the research and healthcare system. This perspective article discusses the challenges of using PROMs at scale, with a focus on multiple sclerosis. AI approaches can enable learning health systems that improve the quality of care by examining the care health systems presently give, as well as accelerating research and innovation. However, we argue that it is crucial that advances in AI - whether relating to research, clinical practice or health systems policy - are not developed in isolation and implemented 'to' people, but in collaboration 'with' them. This implementation of science with patient input, which is at the heart of the Global PROs for Multiple Sclerosis (PROMS) Initiative, will ensure that we maximize the potential benefits of AI for people with MS, whilst avoiding unintended consequences.

Authors

  • Anne Helme
    Multiple Sclerosis International Federation, London, United Kingdom.
  • Dipak Kalra
    The European Institute for Innovation through Health Data, Ghent, Belgium.
  • Giampaolo Brichetto
    Department of Research, Italian Multiple Sclerosis Foundation, Genoa, Italy. giampaolo.brichetto@aism.it.
  • Guy Peryer
    Multiple Sclerosis Society UK, London, United Kingdom.
  • Patrick Vermersch
    Univ. Lille, InsermU1172 LilNCog, CHU Lille, FHU Precise, Lille, France.
  • Helga Weiland
    Multiple Sclerosis South Africa, Western Cape, South Africa.
  • Angela White
    GlaxoSmithKline, Ware, UK.
  • Paola Zaratin
    Research Department, Italian Multiple Sclerosis Foundation, Genoa, Italy.